EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

Eric Hahnen iD, Jan Hauke, Karen Gelmon iD, Frederik Marmé iD, Corinna Ernst iD, Miguel Martin iD, Michael Untch iD, Hervé Bonnefoi, Erik Knudsen iD, Seock-Ah Im iD, Angela DeMichele iD, Laura Van't Veer iD und 26 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00742 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Eric Hahnen und 37 weiteren Autor:innen. Beteiligte Einrichtung: Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, Cologne, Germa…. Hauptthemen laut MEDLINE: Breast Neoplasms, Piperazines, Pyridines, BRCA1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The PENELOPE-B trial (ClinicalTrials.gov identifier: NCT01864746 ) recruited patients with hormone receptor+/human epidermal growth factor receptor 2– early breast cancer without a pathological complete response after taxane-containing neoadjuvant chemotherapy and at a high risk of relapse. Patients were randomly assigned (1:1) to receive 13 cycles of palbociclib once daily or placebo on days 1-21 in a 28-day cycle in addition to endocrine therapy (ET). PENELOPE-B did not show improved invasive disease-free survival (iDFS) after adding palbociclib to ET. This retrospective analysis investigated the impact of germline pathogenic variant (PV) status of BRCA1/2 and non- BRCA1/2 cancer predisposition genes on the outcomes of PENELOPE-B trial patients. METHODS In total, 445 patients were sampled following a case-cohort design and 442 were analyzed for germline PVs. Statistical analyses were performed for time-to-event end points (iDFS, distant disease-free survival [DDFS], and overall survival [OS]). RESULTS Of the 442 patients, 42 carried PVs in any cancer predisposition gene; 15 carried BRCA1/2 PVs. Irrespective of the treatment arms, PV status was not a prognostic factor. Regarding the treatment arms in BRCA1/2 PV carriers, numerically better 3-year outcomes were observed in the palbociclib arm (iDFS, 95%; DDFS, 95%; OS, 100%) than in the placebo arm (iDFS, 72.8%; DDFS, 72.8%; OS, 87.5%; hazard ratios palbociclib v placebo 0.349 [iDFS] and 0.562 [DDFS], not calculated for OS, too few events). In patients without BRCA1/2 PVs, the differences in 3-year outcomes were negligible. PVs in non- BRCA1/2 cancer predisposition genes did not influence the efficacy of palbociclib, although gene-specific effects could not be excluded. CONCLUSION Patients with BRCA1/2 PVs had numerically better outcomes after palbociclib. However, the number of BRCA1/2 carriers was small. Larger randomized clinical trials should consider the PV status to further evaluate whether BRCA1/2 PV carriers benefit from cyclin-dependent kinase 4 and 6 inhibitor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPiperazinesPyridinesBRCA1 ProteinBRCA2 ProteinAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedRetrospective StudiesAdultErb-b2 Receptor Tyrosine KinasesGenetic Predisposition to DiseaseAgedGerm-Line MutationReceptors, Estrogen

Substanzen

PiperazinesPyridinesErb-b2 Receptor Tyrosine KinasesBRCA1 ProteinBRCA2 ProteinAntineoplastic Agents, HormonalReceptors, EstrogenpalbociclibBRCA1 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, Cologne, Germany.
  • BC Cancer, Vancouver, BC, Canada.
  • Universitätsfrauenklinik Mannheim, Mannheim, Germany.
  • Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain.
  • Helios Kliniken Berlin Buch, Berlin, Germany.
  • Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France.

ORCID-Profile: Eric Hahnen, Karen Gelmon, Frederik Marmé, Corinna Ernst, Miguel Martin, Michael Untch, Erik Knudsen, Seock-Ah Im, Angela DeMichele, Laura Van't Veer, Sung-Bae Kim, Harry Bear, Nicholas Turner, Martin Filipits, Lesley-Ann Martin, Peter A Fasching, Kerstin Becker, Catherine M Kelly, Toralf Reimer, Masakazu Toi, Hope S Rugo, Carsten Denkert, Michael Gnant, Valentina Nekljudova, Sibylle Loibl

Zitieren

APA

Hahnen, E., Hauke, J., Gelmon, K., Marmé, F., Ernst, C., Martin, M., Untch, M., Bonnefoi, H., Knudsen, E., Im, S. A., DeMichele, A., Van't Veer, L., Kim, S. B., Bear, H., McCarthy, N., Rhiem, K., Turner, N., Witkiewicz, A., Rojo, F., …, & Loibl, S. (2025). BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. JCO Precision Oncology. https://doi.org/10.1200/po-24-00742

Vancouver

Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, et al. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. JCO Precision Oncology. 2025. doi:10.1200/po-24-00742

BibTeX
@article{Hahnen2025,
  author = {Hahnen, Eric and Hauke, Jan and Gelmon, Karen and Marmé, Frederik and Ernst, Corinna and Martin, Miguel and Untch, Michael and Bonnefoi, Hervé and Knudsen, Erik and Im, Seock-Ah and DeMichele, Angela and Van't Veer, Laura and Kim, Sung-Bae and Bear, Harry and McCarthy, Nicole and Rhiem, Kerstin and Turner, Nicholas and Witkiewicz, Agnieszka and Rojo, Federico and Filipits, Martin and Martin, Lesley-Ann and Fasching, Peter A and Schem, Christian and Becker, Kerstin and García-Sáenz, José A and Kelly, Catherine M and Reimer, Toralf and Toi, Masakazu and Rugo, Hope S and Denkert, Carsten and Gnant, Michael and Makris, Andreas and Liu, Yuan and Valota, Olga and Felder, Bärbel and Weber, Karsten and Nekljudova, Valentina and Loibl, Sibylle},
  title = {BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00742}
}
Kostenlos starten →